Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$21.21 USD
+0.26 (1.24%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.21 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Amphastar Pharmaceuticals, Inc. has a PEG ratio of 4.49 compared to the Medical - Generic Drugs industry's PEG ratio of 5.07.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMPH 21.21 +0.26(1.24%)
Will AMPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Bausch Health (BHC) Lags Q2 Earnings Estimates
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Amphastar (AMPH) a New Buy Stock
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks
Other News for AMPH
Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More
Amphastar Pharmaceuticals Inc (AMPH) Announces Second Quarter 2025 Earnings Release and ...
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August ...
Amphenol (AMPH) Anticipates Strong Q3 Revenue Growth Amid Electronics Boom | AMPH Stock News
Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c